P/E ratio for ImmunoPrecise Antibodies (IPA)
P/E ratio as of June 2024 (TTM): -1.61
According to ImmunoPrecise Antibodies's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.60527. At the end of 2022 the company had a P/E ratio of -6.11.
P/E ratio history for ImmunoPrecise Antibodies from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -6.11 | -25.54% |
| 2021 | -8.21 | -92.28% |
| 2020 | -106 | 2264.59% |
| 2019 | -4.50 | -24.24% |
| 2018 | -5.94 | 221.4% |
| 2017 | -1.85 | |
| 2015 | -0.2261 | -95.47% |
| 2014 | -4.99 | -796.74% |
| 2013 | 0.7169 | -143.24% |
| 2012 | -1.66 | -27.8% |
| 2011 | -2.30 | 432.39% |
| 2010 | -0.4313 | -89.47% |
| 2009 | -4.10 | 210.03% |
| 2008 | -1.32 | -72.88% |
| 2007 | -4.87 | -38.27% |
| 2006 | -7.89 | -131.3% |
| 2005 | 25.2 | -293.83% |
| 2004 | -13.0 | -11.7% |
| 2003 | -14.7 | 390.05% |
| 2002 | -3.01 | 27.68% |
| 2001 | -2.35 |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.